Amgen has announced positive topline results from the Phase 3 FIGHT trial evaluating bemarituzumab in combination with chemotherapy for advanced gastric and gastroesophageal junction (GEJ) cancer.
In a breakthrough for oncology, Johnson & Johnson has announced promising early results from a Phase 1b clinical trial for its second-generation CAR T-cell therapy, [Read More…]
The VENTANA MET (SP44) RxDx Assay detects the MET, or c-Met, protein, which is overexpressed in about 25% of advanced NSQ-NSCLC patients with EGFR wild-type.
Immunotherapies and other cancer treatments don’t work well on “cold” tumors, also known as immunological deserts, because they usually have few T cells.
According to the researchers, these recurring patterns suggest potential therapeutic targets meant to prevent or slow the progression of cancer.
Physicians were required to decide on cancer patients’ treatments, initially without the aid of technology and later with AI’s support.
According to the study, when a cell spreads out over a rigid surface, the nuclear lamina, which serves as a scaffold to help the nucleus maintain its form and structure, becomes taut and unwrinkled.
The treatment of numerous severe illnesses, including cancer, may improve as a result of a recently published study headed by Wayne State University on a [Read More…]
However, it’s also known that TET2 mutations can result in conditions other than cancer. A portion of persons over the age of 70 also had TET2 mutations, which raise the risk of diabetes, heart disease, stroke, and other inflammatory diseases as well as CHIP.
The study investigated if cancer status differed according to individuals’ RAS genetic variations.
